Out-licensing

A Peptide Targeting to Tumour Blood Vessels of Lung Cancer: Anti-Angiogenesis Targeting Therapy and Diagnosis of Solid Tumours

Introduction/Background

Antiangiogenic therapies for the treatment of cancers have the promise of high efficacy and low toxicity.

Aims/Hypothesis

We are focusing our research on the development of anti-angiogenesis targeting therapy for cancer.

Research

A peptide marker was identified and characterized to home specifically to tumour blood vessels. It recognizes the neovasculature in tumours but not in normal blood vessels in SCID mice bearing human tumours. This peptide also binds stimulated HUVECs and blood vessels of human lung cancer biopsy specimens. The targeting peptide is a good candidate for targeted drug delivery to solid tumours and may prove useful for translational applications targeting tumour vasculature.

Conventional chemotherapeutic agents react not only with tumour cells but also normal cells. This tumour-homing peptide provides an effective solution to this problem by specifically targeting tumour vessels. Several types of solid tumours can be treated by this targeting peptide conjugated with cancer chemotherapeutics.

Conclusion

We have elucidated a peptide targeting to tumour blood vessels of lung cancer.

Relevance/Opportunity

We are currently seeking licensing or codevelopment partnerships. Please enquire quoting reference no. 10A-960105.

Preclinical

US pending, TW pending, PCT pending